Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression

Leukemia Research

Volumn 34, Issue 9, 2010, Pages

  Papageorgiou, Sotirios G ^a   Pappa, Vasiliki ^a   Economopoulou, Christina ^a   Tsirigotis, Panagiotis ^a   Konsioti, Frida ^a   Ionnidou, Eleni Dikaia ^a   Chondropoulos, Spyros ^a   Vasilatou, Diamantina ^a   Papageorgiou, Efstathios ^a   Economopoulos, Theofanis ^a   Dervenoulas, John ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DASATINIB; DIURETIC AGENT; FLUDARABINE; IDARUBICIN; IMATINIB;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME ABERRATION; COLLAGEN DISEASE; CONTINUOUS INFUSION; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE TRANSFUSION; FIBROSIS; GENETIC SCREENING; HEPATOMEGALY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; KARYOTYPING; LABORATORY TEST; LETTER; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; PANCYTOPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE TRANSFUSION;

EID: 77955276590     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.032     Document Type: Letter

References (9)

1. Jabbour E., Cortes J.E., Kantarjian H.M. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009, 1:3-10.
2. Soupir C.P., Vegilio J.A., Dal Cin P., Muzikansky A., Kantarjian H., Jones D., et al. Philadelphia chromosome-positive acute myeloid leukaemia: a rare aggressive leukaemia with clinicopathologic features distinct from chronic myeloid blast crisis. Am J Clin Pathol 2007, 127:642-650.
3. Tallman M.S., Neuberg D., Bennett J.M., Francois C.G., Paietta E., Wiernick P.H., et al. Acute megakaryoblastic leukaemia: the Eastern Cooperative Oncology Group experience. Blood 2000, 96:2405-2411.
4. Kaloutsi V., Hadjileontis C., Tsatalas C., Sambani C., Kastopoulos I., Papadimitriou C. Occurrence of a variant Philadelphia translocation t (10, 22), in de novo acute megakaryoblastic leukaemia. Cancer Gen Cytogenetic 2004, 152:52-55.
5. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
6. Abdelhalim A., Barcos M., Block A., Sait S., Starostik P., Wetzler M., et al. Remission of Philadelphia chromosome-positive central nervous system leukaemia after dasatinib therapy. Leukemia Lymphoma 2007, 48(5):1053-1056.
7. Porkka K., Koskenvesa P., Lundan T., Rimpilainen J., Mustjoki S., Smykla R., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome positive leukaemia. Blood 2008, 112:1005-1012.
8. Frigeri F., Arcamone M., Luciano L., Di Francia R., Pane F., Pinto A. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia positive leukemia. Blood 2009, 113:5028-5029.
9. Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B., Recher C. A critical role for Lyn in acute myeloid leukaemia. Blood 2008, 111:2269-2279.